# @propublica on Instagram

- **Type:** Video
- **Original URL:** https://www.instagram.com/p/DGQzm2Wurmh
- **Gondola URL:** https://gondola.cc/posts/34003592-propublica-instagram
- **Thumbnail:** https://img.gondola.cc/tr:w-,h-,fo-auto/postThumbnails/085ee5a36d.jpg
- **Posted:** 2025-02-19T17:30:02.000+00:00
- **Account Owner:** ProPublica (@propublica) — https://gondola.cc/propublica

## Caption

The gene therapy Zolgensma has helped children born with a fatal disease, spinal muscular atrophy, grow up to run and play. But the cost is stunning: $2 million per dose. The drug’s price set the standard for other, even more expensive gene therapies — like one that goes for $4.25 million per dose.

Taxpayers and charities subsidized much of the science that led to Zolgensma. Yet executives, venture-capital backers and a pharma giant reaped the profits. Meanwhile, the drug’s cost adds to the nation’s ballooning bill for prescription drugs and puts Zolgensma out of reach for kids in many low- and middle-income countries.

Zolgensma’s story upends the widely held conception that high prices reflect huge industry investments in innovation.

To read our full investigation, go to the link in bio.

📰: Robin Fields
🎨: owen_gent , special to ProPublica
🎥: josesepulvedatv 

#venturecapital #biotech #novartis #genetherapy

## Stats

- **Views:** 14,930
- **Likes:** 1,099
- **Shares:** 0
- **Comments:** 22

## Tags

novartis, genetherapy, biotech, venturecapital

---
Copyright (c) Gondola